Skip to Main Content Menu Search Site

How can we train the immune system to fight cancer?

Previous Next

The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types.

Credit: Wyss Institute at Harvard University

Close menu